Skip to main content
. 2025 May 6;8:100171. doi: 10.1016/j.esmogo.2025.100171

Figure 1.

Figure 1

Kaplan–Meier estimates for 92 patients with advanced esophageal squamous cell carcinoma treated with an immune checkpoint inhibitor (ICI)-based therapy. (A) Progression-free survival (PFS) and (B) overall survival (OS) in ICI + chemotherapy (chemo). (C) PFS and (D) OS in nivolumab + ipilimumab (nivo + ipi). CI, confidence interval; NR; not reached.